<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222936</url>
  </required_header>
  <id_info>
    <org_study_id>S075LBH501</org_study_id>
    <nct_id>NCT01222936</nct_id>
  </id_info>
  <brief_title>LBH Phase II in Small Cell Lung Cancer (SCLC)</brief_title>
  <official_title>A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Patients With Advanced Small Cell Lung Cancer (SCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Europe New Drug Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern Europe New Drug Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SCLC is the most aggressive and lethal form of lung cancer, typically very sensitive to&#xD;
      cytotoxic therapy when first diagnosed, but associated with a high incidence of tumour&#xD;
      relapse and a very poor life expectancy. Combination chemotherapy based on cisplatin or&#xD;
      carboplatin and etoposide represents the most widely used regimen. Despite of the high&#xD;
      response rate, approximately 80% of patients with limited disease and nearly all patients&#xD;
      with extended disease develop disease relapse or progression. Topotecan is, at present, the&#xD;
      only approved second line treatment in Europe.&#xD;
&#xD;
      The search of a new therapeutic agent that could alter the natural history of SCLC would be&#xD;
      an important goal to be reached. LBH589 (Panobinostat) is a histone deacetylase (HDAC)&#xD;
      inhibitor available for intravenous and oral administration. LBH589 could be classified as&#xD;
      PAN-DAC inhibitor targeting both histone and non histone proteins and as such it could be&#xD;
      suitable for combination with cytotoxics. Three phase I dose escalation studies with both the&#xD;
      intravenous and the oral formulation of LBH589, examining various dose schedules of&#xD;
      administration have been conducted in advanced solid tumours and haematological malignancies.&#xD;
&#xD;
      Single agent activity was observed in phase I in patients with haematological cancer. In&#xD;
      solid tumours one response (Hormone-refractory Prostatic Cancer) and some prolonged&#xD;
      stabilizations have been observed with intravenous formulation. Phase II studies are now in&#xD;
      progress.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>12-18 weeks (foreseen participation of the patient in the study)</time_frame>
    <description>Objective response rate measured according to the RECIST (Response Evaluation Criteria In Solid Tumours).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of antitumor activity</measure>
    <time_frame>12-18 weeks (foreseen participation of the patient in the study)</time_frame>
    <description>Time-to-progression, duration of response and disease stabilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug safety profile</measure>
    <time_frame>28 days following the last dose</time_frame>
    <description>Evaluation of adverse events, physical examination, vital signs, concomitant medications, laboratory (hematology and chemistry) and instrumental data (i.e. ECG) considered for safety analyses</description>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Small Cell Lung Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LBH581</intervention_name>
    <description>25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.</description>
    <other_name>Panobinostat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological/cytological diagnosis of SCLC, mixed small and non small cell tumours are&#xD;
             excluded&#xD;
&#xD;
          2. ≤ 2 prior chemotherapy lines&#xD;
&#xD;
          3. Progression after, and not during, last previous chemotherapy treatment&#xD;
&#xD;
          4. Age ≥ 18 and ≤ 75 years&#xD;
&#xD;
          5. Life expectancy of at least 3 months&#xD;
&#xD;
          6. ECOG Performance Status 0-1&#xD;
&#xD;
          7. At least one measurable lesion according to modified RECIST criteria defined as ≥ 1&#xD;
             lesion with longest diameter ≥ 20 mm by conventional techniques or ≥ 10 mm with spiral&#xD;
             CT scan. In case of solitary measurable lesion, histological confirmation is not&#xD;
             required.&#xD;
&#xD;
          8. Adequate haematological function:&#xD;
&#xD;
               -  haemoglobin ≥ 9 g/dl&#xD;
&#xD;
               -  platelet count ≥ 100,000/mm3&#xD;
&#xD;
               -  neutrophils count ≥ 1,500/mm3&#xD;
&#xD;
          9. Adequate liver and renal functions:&#xD;
&#xD;
               -  Total serum bilirubin ≤ 1.5 x UNL&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x UNL or 24 hours creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 x UNL or ≤ 5.0 x UNL if the transaminase elevation is due to&#xD;
                  hepatic involvement&#xD;
&#xD;
               -  Albumin ≥ 2.5 g/dl&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 x UNL&#xD;
&#xD;
         10. Fertile patients must use effective contraception during and for ≥ 6 weeks after&#xD;
             completion of study therapy&#xD;
&#xD;
         11. Ability to signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Progression while on previous chemotherapy&#xD;
&#xD;
          2. Other chemotherapy treatment &lt; 4 weeks prior to enrolment&#xD;
&#xD;
          3. Presence of active infection&#xD;
&#xD;
          4. A known history of HIV positivity&#xD;
&#xD;
          5. Participation to any investigational drug study &lt; 4 weeks preceding study enrolment&#xD;
&#xD;
          6. Radiotherapy involving &gt; 30% of the active bone marrow&#xD;
&#xD;
          7. Thoracic and brain radiotherapy &lt; 4 weeks prior to enrolment. Palliative radiotherapy&#xD;
             is allowed during study treatment&#xD;
&#xD;
          8. Presence of any serious neurological or psychiatric disorder&#xD;
&#xD;
          9. Impaired cardiac function, including any one of the following:&#xD;
&#xD;
               -  Complete Left Bundle Branch Block or obligate use of a cardiac pacemaker or&#xD;
                  congenital long QT syndrome or history or presence of atrial or ventricular&#xD;
                  tachyarrhythmias or clinically significant resting bradycardia (&lt; 50 beats per&#xD;
                  minute) or QTcF &gt; 480 msec on screening ECG or Right Bundle Branch block + left&#xD;
                  anterior hemiblock (biphasic block)&#xD;
&#xD;
               -  Acute MI ≤ 3 months prior to starting study drug&#xD;
&#xD;
               -  Other clinically significant heart disease (e.g. congestive heart failure,&#xD;
                  previous history angina pectoris, uncontrolled hypertension, history of labile&#xD;
                  hypertension or arrhythmia, or history of poor compliance with an&#xD;
                  antihypertensive regimen)&#xD;
&#xD;
               -  Any other case of current abnormal cardiac functionality or history of cardiac&#xD;
                  disease causing LVEF &lt; 45% as determined by ECHO&#xD;
&#xD;
         10. Known hypersensitivity/allergic reaction to the study product&#xD;
&#xD;
         11. Presence of uncontrolled intercurrent illness or any condition which in the judgement&#xD;
             of the investigator would place the subject at undue risk or interfere with the&#xD;
             results of the study.&#xD;
&#xD;
         12. Previous or current concomitant malignancy at other site, other than basal or squamous&#xD;
             cell carcinoma of the skin and carcinoma in situ of the uterine cervix, within 3&#xD;
             years.&#xD;
&#xD;
         13. Symptomatic or progressive brain metastases&#xD;
&#xD;
         14. Patients with an active bleeding diathesis or on anticoagulants Therapeutic doses of&#xD;
             sodium warfarin (Coumadin) are not allowed. Low doses of Coumadin (e.g., ≤ 2 mg/day)&#xD;
             for line patency are allowed&#xD;
&#xD;
         15. Pregnant or lactating women&#xD;
&#xD;
         16. Concomitant use of CYP3A4/5 inhibitors or inducers, or drug that prolong the QT&#xD;
             interval and/or induce torsades ventricular arrythmia, where the treatment can not be&#xD;
             discontinued or switched to a different medication prior to starting study drug.&#xD;
&#xD;
         17. Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF,&#xD;
             GMCSF) ≤ 2 weeks prior to starting study drug.&#xD;
&#xD;
         18. Unable or unwilling to comply with all study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo De Marinis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliera San Camillo Forlanini</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Onkologie und Haematologie</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel Innere Medizin</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;S. G. Moscati&quot;</name>
      <address>
        <city>Avellino</city>
        <state>AV</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Ricerca sul Cancro</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncologia Medica</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore di Parma</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00151</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. San. Ospedaliera Molinette S. Giovanni Battista di Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>October 11, 2010</study_first_submitted>
  <study_first_submitted_qc>October 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>October 14, 2010</last_update_submitted>
  <last_update_submitted_qc>October 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Scientific Director</name_title>
    <organization>SENDO Tech s.r.l.</organization>
  </responsible_party>
  <keyword>LBH581</keyword>
  <keyword>Panobinostat</keyword>
  <keyword>Small Cell Lung Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

